Core Viewpoint - Beida Pharmaceutical has completed a share transfer with Garden Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical, focusing on high-barrier technology in the biopharmaceutical sector [1] Group 1: Company Strategy - The company aims to leverage its advantages in the biopharmaceutical field by enhancing its ecosystem around high-barrier technology [1] - The investment of 50 million RMB in Zhixing Pharmaceutical is part of the company's strategy to strengthen its position in the market [1] Group 2: Zhixing Pharmaceutical Overview - Zhixing Pharmaceutical specializes in the development of high-end inhalation formulations and has established a robust R&D and production system [1] - The company has successfully built a leading domestic research platform for aerosol formulations, overcoming key technical challenges such as particle size control and process stability [1] Group 3: Product Pipeline - Zhixing Pharmaceutical has three products in its pipeline targeting asthma and COPD, all of which have completed bioequivalence (BE) testing [1] - The product "Fluticasone Propionate Nebulized Suspension" is nearing market application, indicating a strong potential for commercialization [1] - The company plans to focus on high-barrier products monopolized by multinational pharmaceutical companies while also developing improved and innovative drugs [1]

Core Viewpoint - The company, Betta Pharmaceuticals (300558), has completed the equity transfer with Huayuan Group, acquiring a 20% stake in Hangzhou Zhixing Pharmaceutical Co., Ltd. for 50 million yuan, indicating a strategic investment in the high-end inhalation formulation sector [1] Group 1: Company Overview - Betta Pharmaceuticals has acquired a 20% stake in Hangzhou Zhixing Pharmaceutical, which specializes in the development of high-end inhalation formulations [1] - The registered capital of Zhixing Pharmaceutical is 2 million yuan, and the investment reflects Betta's commitment to expanding its portfolio in the respiratory therapy market [1] Group 2: Product Pipeline - Zhixing Pharmaceutical has a robust product pipeline with three products in development targeting asthma and COPD, including: - Budesonide and Formoterol inhalation powder - Fluticasone Propionate inhalation suspension - Budesonide inhalation suspension - All three products have completed bioequivalence (BE) trials, with the Fluticasone Propionate inhalation suspension nearing market application [1]